2.要約中間連結財務諸表及び主な注記

(1)要約中間連結財政状態計算書

 

 

 

 

 

(単位:百万円)

 

 

 

前連結会計年度末

(2025年3月31日)

 

当中間連結会計期間末

(2025年9月30日)

資産

 

 

 

 

 

流動資産

 

 

 

 

 

現金及び現金同等物

 

 

55,241

 

65,291

営業債権及びその他の債権

 

 

42,292

 

42,967

棚卸資産

 

 

42,500

 

47,629

その他の金融資産

 

 

3,244

 

3,167

その他の流動資産

 

 

6,461

 

6,097

流動資産合計

 

 

149,740

 

165,153

非流動資産

 

 

 

 

 

有形固定資産

 

 

34,531

 

34,811

無形資産

 

 

48,315

 

47,155

使用権資産

 

 

2,781

 

2,556

その他の金融資産

 

 

39,492

 

38,237

繰延税金資産

 

 

5,597

 

5,964

その他の非流動資産

 

 

3,177

 

3,158

非流動資産合計

 

 

133,897

 

131,884

資産合計

 

 

283,637

 

297,037

 

 

 

 

 

 

 

 

 

 

 

 

 

(単位:百万円)

 

 

 

前連結会計年度末

(2025年3月31日)

 

当中間連結会計期間末

(2025年9月30日)

負債及び資本

 

 

 

 

 

負債

 

 

 

 

 

流動負債

 

 

 

 

 

営業債務及びその他の債務

 

 

16,857

 

17,024

その他の金融負債

 

 

305

 

240

リース負債

 

 

1,348

 

1,370

未払法人所得税

 

 

4,705

 

4,971

その他の流動負債

 

 

7,100

 

7,419

流動負債合計

 

 

30,316

 

31,027

非流動負債

 

 

 

 

 

その他の金融負債

 

 

233

 

234

リース負債

 

 

1,374

 

1,160

退職給付に係る負債

 

 

4,313

 

4,344

その他の非流動負債

 

 

59

 

59

非流動負債合計

 

 

5,980

 

5,799

負債合計

 

 

36,297

 

36,826

資本

 

 

 

 

 

資本金

 

 

5,174

 

5,174

資本剰余金

 

 

4,491

 

4,512

利益剰余金

 

 

222,640

 

236,209

自己株式

 

 

2,459

 

2,440

その他の資本の構成要素

 

 

17,181

 

16,441

親会社の所有者に帰属する持分合計

 

 

247,028

 

259,897

非支配持分

 

 

312

 

314

資本合計

 

 

247,340

 

260,211

負債及び資本合計

 

 

283,637

 

297,037

 

 

E0093145160日本新薬株式会社Nippon Shinyaku Co.,Ltd.四半期第7号参考様式 [IFRS](連結)(一般2Q)IFRStrueCTE2025-04-012025-09-30HY2026-03-312024-04-012024-09-302025-03-311falsefalsefalse451602024-04-012024-09-30jpcrp_cor:ReportableSegmentsMember451602024-04-012024-09-30tse-scediffr-45160:MedicineReportableSegmentMember451602024-04-012024-09-30tse-scediffr-45160:FunctionalFoodsReportableSegmentMember451602024-04-012024-09-30jpcrp_cor:ReconcilingItemsMember451602025-04-012025-09-30jpcrp_cor:ReportableSegmentsMember451602025-04-012025-09-30tse-scediffr-45160:MedicineReportableSegmentMember451602025-04-012025-09-30tse-scediffr-45160:FunctionalFoodsReportableSegmentMember451602025-04-012025-09-30jpcrp_cor:ReconcilingItemsMember451602025-09-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602025-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-09-30jpigp_cor:NonControllingInterestsIFRSMember451602024-03-31451602025-03-31451602024-04-012024-09-30451602024-09-30451602025-04-012025-09-30451602025-09-30451602025-11-14451602024-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602024-03-31jpigp_cor:ShareCapitalIFRSMember451602024-03-31jpigp_cor:CapitalSurplusIFRSMember451602024-03-31jpigp_cor:RetainedEarningsIFRSMember451602024-03-31jpigp_cor:TreasurySharesIFRSMember451602024-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602024-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602024-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602024-03-31jpigp_cor:NonControllingInterestsIFRSMember451602025-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602025-03-31jpigp_cor:ShareCapitalIFRSMember451602025-03-31jpigp_cor:CapitalSurplusIFRSMember451602025-03-31jpigp_cor:RetainedEarningsIFRSMember451602025-03-31jpigp_cor:TreasurySharesIFRSMember451602025-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602025-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602025-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-03-31jpigp_cor:NonControllingInterestsIFRSMember451602024-04-012024-09-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602024-04-012024-09-30jpigp_cor:ShareCapitalIFRSMember451602024-04-012024-09-30jpigp_cor:CapitalSurplusIFRSMember451602024-04-012024-09-30jpigp_cor:RetainedEarningsIFRSMember451602024-04-012024-09-30jpigp_cor:TreasurySharesIFRSMember451602024-04-012024-09-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602024-04-012024-09-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602024-04-012024-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602024-04-012024-09-30jpigp_cor:NonControllingInterestsIFRSMember451602024-09-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602024-09-30jpigp_cor:ShareCapitalIFRSMember451602024-09-30jpigp_cor:CapitalSurplusIFRSMember451602024-09-30jpigp_cor:RetainedEarningsIFRSMember451602024-09-30jpigp_cor:TreasurySharesIFRSMember451602024-09-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602024-09-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602024-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602024-09-30jpigp_cor:NonControllingInterestsIFRSMember451602025-04-012025-09-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602025-04-012025-09-30jpigp_cor:ShareCapitalIFRSMember451602025-04-012025-09-30jpigp_cor:CapitalSurplusIFRSMember451602025-04-012025-09-30jpigp_cor:RetainedEarningsIFRSMember451602025-04-012025-09-30jpigp_cor:TreasurySharesIFRSMember451602025-04-012025-09-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602025-04-012025-09-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602025-04-012025-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-04-012025-09-30jpigp_cor:NonControllingInterestsIFRSMember451602025-09-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602025-09-30jpigp_cor:ShareCapitalIFRSMember451602025-09-30jpigp_cor:CapitalSurplusIFRSMember451602025-09-30jpigp_cor:RetainedEarningsIFRSMember451602025-09-30jpigp_cor:TreasurySharesIFRSMember451602025-09-30jpigp_cor:OtherComponentsOfEquityIFRSMemberiso4217:JPYxbrli:sharesiso4217:JPYxbrli:pure